NCT06092788View on ClinicalTrials.gov

Safety, Pharmacokinetics (PK) and Relative Bioavailability of NTP42:KVA4 as a Solid Oral Dose

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

November 24, 2023

Primary Completion Date

January 17, 2024

Study Completion Date

January 17, 2024

Conditions
Healthy
Interventions
DRUG

NTP42:KVA4 Capsule

Single doses of NTP42:KVA4 administered to healthy volunteers as a capsule

DRUG

NTP42:KVA4 Liquid

Single doses of NTP42:KVA4 administered to healthy volunteers as a liquid

Trial Locations (1)

NW10 7EW

Hammersmith Medicines Research, London

Sponsors
All Listed Sponsors
collaborator

Hammersmith Medicines Research

OTHER

lead

ATXA Therapeutics Limited

INDUSTRY

NCT06092788 - Safety, Pharmacokinetics (PK) and Relative Bioavailability of NTP42:KVA4 as a Solid Oral Dose | Biotech Hunter | Biotech Hunter